No retraction, correction or concern found when last checked on Oct 16, 2026.

LeishVet guidelines for the practical management of canine leishmaniosis

Laia Solano-Gallego, Guadalupe Miró, Alek Koutinas and 6 more

Parasites & Vectors · 2011 · Review

Abstract

The LeishVet group has formed recommendations designed primarily to help the veterinary clinician in the management of canine leishmaniosis. The complexity of this zoonotic infection and the wide range of its clinical manifestations, from inapparent infection to severe disease, make the management of canine leishmaniosis challenging. The recommendations were constructed by combining a comprehensive review of evidence-based studies, extensive clinical experience and critical consensus opinion discussions. The guidelines presented here in a short version with graphical topic displays suggest standardized and rational approaches to the diagnosis, treatment, follow-up, control and prevention of canine leishmaniosis. A staging system that divides the disease into four stages is aimed at assisting the clinician in determining the appropriate therapy, forecasting prognosis, and implementing follow-up steps required for the management of the leishmaniosis patient.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 16, 2026. Paragraph numbers are ours, so an answer can point at one.

Background

1Canine leishmaniosis (CanL) due to Leishmania infantum is a major global zoonosis potentially fatal to humans and dogs, which comprise the main reservoir of infection to humans. CanL is endemic in more than 70 countries in the world. It is present in regions of southern Europe, Africa, Asia, South and Central America and has been reported also in the United States of America (USA). It is also an important concern in non-endemic countries where imported sick or infected dogs constitute a veterinary and public health problem.

2CanL is manifested by a broad spectrum of clinical signs and degrees of severity, and there is insufficient scientific agreement on the management of this disease. LeishVet is a group of veterinary scientists from academic institutes in Europe and the Mediterranean basin with a main clinical and scientific interest in CanL. The main goal of LeishVet is to develop consensus recommendations that would represent the most current understanding of L. infantum infection in dogs based on recent evidence-based literature and clinical experience. The objective of these guidelines is to help practitioners in the clinical management of CanL with emphasis on diagnosis, clinical staging, treatment, clinical monitoring, prognosis and prevention.

Life cycle and transmission

3Leishmania completes its life cycle in two hosts, a phlebotomine sand fly vector, which transmits the flagellated infective promastigote form, and a mammal, where the intracellular amastigote form develops and replicates (Figure 1). Sand flies are the only arthropods that are adapted for biological transmission of Leishmania. The relatively low proportion of sand flies harbouring L. infantum (0.5 - 3%) is sufficient for maintaining the infection in endemic areas. Non-sand fly modes of transmission have also been described but their role in the natural history and epidemiology of leishmaniosis remains unclear (Figure 1). Proven modes of non-sand fly transmission include infection through transfused blood products from blood donors which are carriers of infection, vertical and venereal transmission. The adequate selection of canine blood donors is of great importance for the prevention of L. infantum infection and recommendations on donor selection are graphically summarized in Figure 2. Suspected yet unproven modes of transmission include: 1) direct dog-to-dog transmission through bites or wounds, which could explain the presence of autochthonous CanL clinical cases in non-endemic areas in the absence of apparent vectors, as described in foxhounds in the USA or in breeding kennels in Europe, and 2) transmission by other hematophagous arthropods such as ticks and fleas (Figure 1).

Distribution and epidemiology

4Socioeconomic and possible climate factors have led to changes in the distribution of CanL in Europe (Figure 3). Leishmania infantum infection has spread northward reaching the foothills of the Alps in northern Italy and of the Pyrenees in France and northern Spain. The large numbers of dogs travelling to southern Europe or imported as companion animals from areas where CanL is endemic have increased the number of clinical cases reported in non endemic countries such as the United Kingdom and Germany.

5Leishmania infantum frequently follows an insidious and chronic pattern of infection. Therefore, CanL is a disease in which infection does not equal clinical illness resulting in a high prevalence of subclinical infection.

6A broad range of immune responses and clinical manifestations have been described in CanL (Figure 4). Infection in dogs may be subclinical or manifested as a self-limiting disease, or a severe, and sometimes, fatal illness. Subclinical infection is not necessarily permanent and factors such as immunosuppression or concomitant diseases could break the equilibrium and lead to the progression of clinical disease in dogs as observed in humans coinfected with human immunodeficiency virus and Leishmania.

7Several predisposing factors for the development of disease have been described including breed, age and genetic background. Some dog breeds such as the Boxer, Cocker Spaniel, Rottweiler and German Shepherd seem to be more susceptible to the development of disease, while others such as the Ibizian Hound rarely develop clinical signs of CanL. The Slc11c1 (Solute carrier family 11 member a1) gene, formerly named N-RAMPI, and certain alleles of the MHC II genes have been associated with susceptibility to CanL. Age seems to be an important factor. The distribution of the disease is bimodal, with the highest prevalence reported in dogs younger than 3 years and older than 8 years.

Clinical manifestations and laboratory abnormalities

8CanL is a systemic disease that may potentially involve any organ, tissue or body fluid and is manifested by nonspecific clinical signs. The most common clinical manifestations and clinicopathological abnormalities found in CanL are listed in Table 1. Skin lesions are the most frequent manifestation among them (Figure 5) and may be seen along with other clinical signs or clinicopathological abnormalities. However, dogs can be presented with other clinical signs unrelated to cutaneous lesions as the main presenting complaint (Figure 6). Renal disease may be the sole clinical manifestation of CanL and it can progress from mild proteinuria to the nephrotic syndrome or to an end stage renal disease. Chronic renal failure is a severe result of disease progression and the main cause of mortality due to CanL. Despite the high prevalence of renal pathology in infected dogs, renal azotemia is relatively an uncommon laboratory finding. The common pathological findings detected by cytology (Figure 7) or histology in CanL are listed in Table 2. However, the variable and nonspecific clinical signs make the list of differential diagnoses wide and extensive.

Diagnosis

9The purposes for which diagnosis of L. infantum infection is carried out are outlined in Figure 8. Due to these different diagnostic indications, it is important to separate Leishmania infection from disease and to apply different diagnostic techniques for each state. The definitions of sick versus clinically healthy infected dogs are shown in Figure 9.

10The diagnosis of CanL is complex as the clinical spectrum is broad and the range of clinicopathological abnormalities based on at least a complete blood count (CBC), biochemical profile and urinalysis can be both wide and non-specific. A thorough clinicopathological diagnostic approach needs to be adapted for each patient when assessing the suspicion of this disease. In addition, dogs with leishmaniosis might be co-infected with other vector borne diseases or suffering from other concomitant infectious or non-infectious diseases making the differential diagnoses more complicated and diverse. Therefore, based on the clinicopathological problem list, a differential diagnosis and specific diagnostic approach would be made for each patient.

11Different specific diagnostic methods have been described for the detection of L. infantum infection in dogs and these are shown in Figure 10. Valid diagnostic tests are essential for the detection of Leishmania infection in sick dogs although they lack 100% sensitivity and specificity. The advantages and disadvantages of the different diagnostic methods are summarized in Table 3.

12The diagnosis of CanL can be made by the detection of specific serum antibodies (IgG) using preferably quantitative serological techniques, such as the immunofluorescence antibody test (IFAT) and enzyme-linked immunosorbent assay (ELISA). Immunochromatography-based assays are easy to use and provide rapid qualitative results on the spot, but their performance is still not optimal. The interpretation of serological qualitative rapid tests is described in Figure 11. It is important to submit samples to a laboratory that runs quantitative serological assays and can provide an endpoint titer (IFAT) or an optical density reading (ELISA) and a classification of the level of antibodies.

13Detection of Leishmania DNA in tissues by PCR allows sensitive and specific diagnosis of infection. PCR can be performed on DNA extracted from tissues, blood, body fluids or even from histopathologic specimens. The different sensitivities of tissues for the detection of L. infantum by PCR and variable sensitivities of PCR techniques are listed in Figure 12. Assays based on the detection of kinetoplast DNA (kDNA) appear to be the most sensitive for direct detection in infected tissues. Real-time PCR allows quantification of the Leishmania parasite load in the tissues of infected dogs, which is useful for the diagnosis and the follow-up during treatment. It is important to highlight that information provided by PCR should not be separated from the data obtained from clinicopathological and serological evaluations.

14A high level of antibodies confirms the diagnosis of CanL in a dog with clinical signs and/or clinicopathological abnormalities compatible with leishmaniosis. However, the presence of a low antibody level is not necessarily indicative of the disease and further work-up is necessary to confirm or exclude clinical leishmaniosis. The diagnostic approach for sick dogs living in an endemic area is shown in Figure 13. The diagnostic approach for sick or healthy dogs living in a non-endemic area that have travelled to an endemic area, should include quantitative serology three months after the beginning of exposure in the endemic area.

Clinical staging, treatment and prognosis

15A system of four clinical stages based on clinical signs, clinicopathological abnormalities and serological status was proposed by the LeishVet group in an effort to cover the wide spectrum of clinical manifestations and degrees of severity found in CanL. Different treatment protocols and prognoses are suggested for each clinical stage as described in Table 4.

16The most common drugs used for treatment of CanL, including dosage, combinations and side effects, are listed in Table 5. Several other candidate medications against CanL have been studied in vitro or in laboratory animals but rarely in controlled clinical trials and they are, therefore, currently not recommended for the routine treatment of CanL.

17The clinical response to treatment of sick dogs can vary from poor to good depending on their overall initial clinicopathological status and their specific response to therapy. Dogs with renal insufficiency are expected to have a lower recovery rate in comparison to those without kidney compromise or only mild proteinuria. Therapy with antileishmanial drugs often leads to clinical cure although treated dogs may continue to harbour the parasite and be infectious to sand flies, but to a lesser extent than pre-treatment.

18The vast majority of dogs experience clinical improvement within the first month of therapy; however, a longer period of therapy may be required for others before improvement is apparent. The frequencies of monitoring and clinicopathological parameters, including serology, to be followed up during treatment of CanL are summarized in Table 6.

19The length of allopurinol treatment depends on the severity of the disease, the clinical and parasitological response to treatment and the individual tolerance to this drug. Some extremely susceptible dogs never reach a point that would allow the discontinuation of allopurinol, while others are capable of controlling infection without the need for extremely lengthy treatment. Allopurinol can be discontinued when the combination of the following criteria is made:

20(1) The presence of complete physical and clinicopathological recovery evaluated by a thorough physical examination, CBC, full biochemistry panel and urinalysis.

21(2) A marked decrease of antibody levels (to negative or borderline by a quantitative serological assay).

22In addition, allopurinol might be discontinued if it is not possible to control or decrease the xanthinuria with low purine diets or by reducing the drug's dosage, to avoid the risk of urolithiasis, if massive xanthine crystalluria is present.

Management of clinically healthy infected dogs in endemic areas

23The management of clinically healthy infected dogs in areas where CanL is endemic is of great importance for practitioners.

24The presence of Leishmania DNA in the blood or other tissues of clinically healthy dogs living in endemic areas indicates that these dogs harbour infection, but they may never develop clinical disease. In contrast, a high positive antibody titer may indicate that an infected dog is heading towards the development of a widespread infection and future development of clinical disease. Therefore, we recommend using serology alone or the combination of serology with PCR for screening healthy dogs. It is recommended to avoid screening clinically healthy dogs only by PCR.

25Healthy dogs should be screened for Leishmania antibodies as an initial indication for the presence of infection if:

261. They are scheduled to travel or be exported to non-endemic areas (Figure 14)

272. They serve as blood donors (Figure 2)

283. Their owners wish to have them monitored at least every 12 months for early detection of infection and the potential to develop disease.

29PCR should be used for the second above indication and as an ancillary test for the first and third above indications.

30The management of a clinically healthy seropositive dog and a clinically healthy seronegative and PCR-positive dog is summarized in Figure 14.

Prevention

31Current preventative measures are mainly based on the use of veterinary registered products containing synthetic pyrethroids, permethrin, or deltamethrin with a repellent effect against sand flies whose efficacy has been demonstrated both experimentally and in field studies. These products are available in spot on formulation or in a collar form and they reduce the risk of new infections and the biting of sand flies on already infected dogs. Other measures useful in the prevention of sand fly bites include: 1) keeping the dog indoors during the sand fly season from dusk to dawn; 2) reducing microhabitats favourable to sand flies such as piles of wood and stones in the vicinity of the house and in other locations where dogs spend time; 3) usage of indoor insecticide treatment.

32Long-acting topical insecticides evaluated in several published field studies should be applied to dogs living or travelling to endemic areas as follows:

33- Permethrin/Imidacloprid spot on formulation: Treatment provides repellent (anti feeding) activity against sand flies (P. perniciosus) for three weeks. Repeat administration every 3 weeks. It should be applied at least 2 days before travelling

34- Deltamethrin collars: Control of feeding by phlebotomine sand flies (P. perniciosus) for a period of 5-6 months. Replace collar every 5-6 months. It should be applied at least 1-2 weeks before travelling.

35Veterinarians and dog owners are advised to carefully check the product's label recommendations and follow the manufacturer's instructions for the correct application and frequency of reapplication. Client education on the maintenance of an appropriate insecticide throughout the period of sand fly activity in the Mediterranean basin (April-November) is also crucial for the protection of dogs.

36Purified Leishmania fraction vaccines appear currently to be the most effective and promising vaccines for dogs. These include the ''fucose mannose ligand'' (FML)-based vaccine and an excreted/secreted antigen purified from specific-medium culture supernatant of L. infantum based vaccine. The FML-based vaccine is currently available commercially in Brazil. The same vaccine has also been proposed as a transmission-blocking vaccine. Recently, another vaccine which contains the recombinant A2 protein and saponin as adjuvant has also been approved in Brazil. In Europe, a different vaccine based on cultured L. infantum purified excreted/secreted antigens has been approved for vaccination of dogs.

37The future for CanL control should be an integrated approach to prevention including vaccination against L. infantum with an effective canine vaccine and the use of long-acting topical insecticide applications. A vaccine would prevent the establishment of infection introduced by the bites of those sand flies that escape the insecticide effect.

Public health considerations

38In Southern Europe, human visceral leishmaniosis caused by L. infantum is a zoonotic disease that affects young children or adults suffering from the Acquired Immune Deficiency Syndrome (AIDS) or immunosuppressive conditions. Dogs are considered the most important peridomestic reservoir of L. infantum infection for humans. However, the ownership of an infected dog does not appear to greatly increase the risk of disease in the family when transmission is already present in the region.

Conclusions

39The complexity of CanL and the wide range of its clinical manifestations, from inapparent infection to severe disease, make the management of CanL challenging. Diagnosis is performed based on clinicopathological manifestations and by confirmation of infection using mainly serological and molecular techniques. A staging system that divides the disease into four stages is aimed at assisting the clinician in determining the appropriate therapy, forecasting prognosis, and implementing follow-up steps required for the management of the leishmaniosis patient. Prevention should be an integrated approach including vaccination against L. infantum with an effective canine vaccine and the application of a topical insecticide.

List of abbreviations

40AIDS: Acquired Immune Deficiency Syndrome; CanL: Canine leishmaniosis; CBC: Complete blood count; CKD: Chronic kidney disease); DNA: Deoxyribonucleic acid; ELISA: Enzyme-linked immunosorbent assay; FML: Fucose mannose ligand; IFAT: Immunofluorescence antibody test; IgG: Immunoglobulin G; IRIS: International Renal Interest Society; kDNA: Kinetoplast DNA; MHC II: Major histocompatibility complex type II; N-RAMPI: Natural Resistance-associated Macrophage Protein one; PCR: Polymerase chain reaction; P.O.: per os; S.C.: subcutaneous; Slc11c1: Solute carrier family 11 member a1; UPC: Urinary protein creatinine ratio; USA: United States of America

Competing interests

41The authors declare that they have no competing interests.

Authors' contributions

42LSG, GM, AK, LC, MGP, LF, PB, GO and GB participated in the formation of the manuscript's content. LSG coordinated the preparation and writing of the manuscript. All authors contributed to helpful discussions, read and approved the final manuscript.

References 89

1.
Gramiccia M Gradoni L The current status of zoonotic leishmaniases and approaches to disease controlInt J Parasitol2005 3511-1211691180
Not in our library10.1016/j.ijpara.2005.07.001
2.
Baneth G Koutinas AF Solano-Gallego L Bourdeau P Ferrer L Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part oneTrends Parasitol2008 247324330
Not in our library10.1016/j.pt.2008.04.001
3.
Petersen CA Barr SC Canine leishmaniasis in North America: emerging or newly recognized?Vet Clin North Am Small Anim Pract2009 39610651074
Not in our library10.1016/j.cvsm.2009.06.008
4.
Shaw SE Langton DA Hillman TJ Canine leishmaniosis in the United Kingdom: a zoonotic disease waiting for a vector?Vet Parasitol2009 1634281285
Not in our library10.1016/j.vetpar.2009.03.025
5.
Owens SD Oakley DA Marryott K Hatchett W Walton R Nolan TJ Newton A Steurer F Schantz P Giger U Transmission of visceral leishmaniasis through blood transfusions from infected English foxhounds to anemic dogsJ Am Vet Med Assoc2001 219810761083
Not in our library10.2460/javma.2001.219.1076
6.
de Freitas E Melo MN da Costa-Val AP Michalick MS Transmission of Leishmania infantum via blood transfusion in dogs: potential for infection and importance of clinical factorsVet Parasitol2006 1371-2159167
Not in our library10.1016/j.vetpar.2005.12.011
7.
Tabar MD Roura X Francino O Altet L Ruiz de Gopegui R Detection of Leishmania infantum by real-time PCR in a canine blood bankJ Small Anim Pract2008 497325328
Not in our library10.1111/j.1748-5827.2008.00542.x
8.
Rosypal AC Troy GC Zajac AM Frank G Lindsay DS Transplacental transmission of a North American isolate of Leishmania infantum in an experimentally infected beagleJ Parasitol2005 914970972
Not in our library10.1645/ge-483r.1
9.
Pangrazio KK Costa EA Amarilla SP Cino AG Silva TM Paixao TA Costa LF Dengues EG Diaz AA Santos RL Tissue distribution of Leishmania chagasi and lesions in transplacentally infected fetuses from symptomatic and asymptomatic naturally infected bitchesVet Parasitol2009 1653-4327331
Not in our library10.1016/j.vetpar.2009.07.013
10.
Boggiatto PM Gibson-Corley KN Metz K Gallup JM Hostetter JM Mullin K Petersen CA Transplacental Transmission of Leishmania infantum as a Means for Continued Disease Incidence in North AmericaPLoS Negl Trop Dis2011 54
Not in our library10.1371/journal.pntd.0001019
11.
Silva FL Oliveira RG Silva TM Xavier MN Nascimento EF Santos RL Venereal transmission of canine visceral leishmaniasisVet Parasitol2009 1601-25559
Not in our library10.1016/j.vetpar.2008.10.079
12.
Shaw SE Langton DA Hillman TJ Canine leishmaniosis in the United Kingdom: A zoonotic disease waiting for a vector?Vet Parasitol2009
Not in our library10.1016/j.vetpar.2009.03.025
13.
Canine Visceral Leishmaniasis, United States and Canada, 2000–2003 · 2006
No notice
14.
Chamaille L Tran A Meunier A Bourdoiseau G Ready P Dedet JP Environmental risk mapping of canine leishmaniasis in FranceParasit Vectors2010 331
Not in our library10.1186/1756-3305-3-31
15.
Coutinho MT Bueno LL Sterzik A Fujiwara RT Botelho JR De Maria M Genaro O Linardi PM Participation of Rhipicephalus sanguineus (Acari: Ixodidae) in the epidemiology of canine visceral leishmaniasisVet Parasitol2005 1281-2149155
Not in our library10.1016/j.vetpar.2004.11.011
16.
Coutinho MT Linardi PM Can fleas from dogs infected with canine visceral leishmaniasis transfer the infection to other mammals?Vet Parasitol2007 1473-4320325
Not in our library10.1016/j.vetpar.2007.04.008
17.
Dantas-Torres F Ticks as vectors of Leishmania parasitesTrends Parasitol2011
Not in our library10.1016/j.pt.2010.12.006
18.
Dantas-Torres F Martins TF de Paiva-Cavalcanti M Figueredo LA Lima BS Brandao-Filho SP Transovarial passage of Leishmania infantum kDNA in artificially infected Rhipicephalus sanguineusExp Parasitol2010 1252184185
Not in our library10.1016/j.exppara.2010.02.003
19.
Paz GF Ribeiro MF Michalsky EM da Rocha Lima AC Franca-Silva JC Barata RA Fortes-Dias CL Dias ES Evaluation of the vectorial capacity of Rhipicephalus sanguineus (Acari: Ixodidae) in the transmission of canine visceral leishmaniasisParasitol Res2010 1062523528
Not in our library10.1007/s00436-009-1697-1
20.
Paz GF Ribeiro MF de Magalhaes DF Sathler KP Morais MH Fiuza VO Brandao ST Werneck GL Fortes-Dias CL Dias ES Association between the prevalence of infestation by Rhipicephalus sanguineus and Ctenocephalides felis felis and the presence of anti-Leishmania antibodies: A case-control study in dogs from a Brazilian endemic areaPrev Vet Med2010 972131133
Not in our library10.1016/j.prevetmed.2010.08.006
21.
Dantas-Torres F Stefania Latrofa M Otranto D Quantification of Leishmania infantum DNA in females, eggs and larvae of Rhipicephalus sanguineusParasit Vectors2011 4156
Not in our library10.1186/1756-3305-4-56
22.
Maroli M Rossi L Baldelli R Capelli G Ferroglio E Genchi C Gramiccia M Mortarino M Pietrobelli M Gradoni L The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectorsTrop Med Int Health2008 132256264
Not in our library10.1111/j.1365-3156.2007.01998.x
23.
Amusategui I Sainz A Aguirre E Tesouro MA Seroprevalence of Leishmania infantum in northwestern Spain, an area traditionally considered free of leishmaniasisAnn N Y Acad Sci2004 1026154157
Not in our library10.1196/annals.1307.022
24.
Menn B Lorentz S Naucke TJ Imported and travelling dogs as carriers of canine vector-borne pathogens in GermanyParasit Vectors2010 334
Not in our library10.1186/1756-3305-3-34
25.
Peters N Sacks D Immune privilege in sites of chronic infection: Leishmania and regulatory T cellsImmunol Rev2006 213159179
Not in our library10.1111/j.1600-065x.2006.00432.x
26.
Solano-Gallego L Morell P Arboix M Alberola J Ferrer L Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serologyJ Clin Microbiol2001 392560563
Not in our library10.1128/jcm.39.2.560-563.2001
27.
Solano-Gallego L Koutinas A Miro G Cardoso L Pennisi MG Ferrer L Bourdeau P Oliva G Baneth G Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosisVet Parasitol2009 1651-2118
Not in our library10.1016/j.vetpar.2009.05.022
28.
Alvar J Aparicio P Aseffa A Den Boer M Canavate C Dedet JP Gradoni L Ter Horst R Lopez-Velez R Moreno J The relationship between leishmaniasis and AIDS: the second 10 yearsClin Microbiol Rev2008 212334359
Not in our library10.1128/cmr.00061-07
29.
Sideris V Papadopoulou G Dotsika E Karagouni E Asymptomatic canine leishmaniasis in Greater Athens area, GreeceEur J Epidemiol1999 153271276
Not in our library10.1023/a:1007526401175
30.
Franca-Silva JC da Costa RT Siqueira AM Machado-Coelho GL da Costa CA Mayrink W Vieira EP Costa JS Genaro O Nascimento E Epidemiology of canine visceral leishmaniosis in the endemic area of Montes Claros Municipality, Minas Gerais State, BrazilVet Parasitol2003 1112-3161173
Not in our library10.1016/s0304-4017(02)00351-5
31.
Solano-Gallego L Llull J Ramos G Riera C Arboix M Alberola J Ferrer L The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infectionVet Parasitol2000 901-23745
Not in our library10.1016/s0304-4017(00)00223-5
32.
Quinnell RJ Kennedy LJ Barnes A Courtenay O Dye C Garcez LM Shaw MA Carter SD Thomson W Ollier WE Susceptibility to visceral leishmaniasis in the domestic dog is associated with MHC class II polymorphismImmunogenetics2003 5512328
Not in our library10.1007/s00251-003-0545-1
33.
Sanchez-Robert E Altet L Utzet-Sadurni M Giger U Sanchez A Francino O Slc11a1 (formerly Nramp1) and susceptibility to canine visceral leishmaniasisVet Res2008 39336
Not in our library10.1051/vetres:2008013
34.
Abranches P Silva-Pereira MC Conceicao-Silva FM Santos-Gomes GM Janz JG Canine leishmaniasis: pathological and ecological factors influencing transmission of infectionJ Parasitol1991 774557561
Not in our library10.2307/3283159
35.
Cardoso L Schallig HD Neto F Kroon N Rodrigues M Serological survey of Leishmania infection in dogs from the municipality of Peso da Regua (Alto Douro, Portugal) using the direct agglutination test (DAT) and fast agglutination screening test (FAST)Acta Trop2004 91295100
Not in our library10.1016/j.actatropica.2004.03.004
36.
Ciaramella P Oliva G Luna RD Gradoni L Ambrosio R Cortese L Scalone A Persechino A A retrospective clinical study of canine leishmaniasis in 150 dogs naturally infected by Leishmania infantumVet Rec1997 14121539543
Not in our library10.1136/vr.141.21.539
37.
Koutinas AF Polizopoulou ZS Saridomichelakis MN Argyriadis D Fytianou A Plevraki KG Clinical considerations on canine visceral leishmaniasis in Greece: a retrospective study of 158 cases (1989-1996)J Am Anim Hosp Assoc1999 355376383
Not in our library10.5326/15473317-35-5-376
38.
Costa FA Goto H Saldanha LC Silva SM Sinhorini IL Silva TC Guerra JL Histopathologic patterns of nephropathy in naturally acquired canine visceral leishmaniasisVet Pathol2003 406677684
Not in our library10.1354/vp.40-6-677
39.
Zatelli A Borgarelli M Santilli R Bonfanti U Nigrisoli E Zanatta R Tarducci A Guarraci A Glomerular lesions in dogs infected with Leishmania organismsAm J Vet Res2003 645558561
Not in our library10.2460/ajvr.2003.64.558
40.
Solano-Gallego L Fernandez-Bellon H Morell P Fondevila D Alberola J Ramis A Ferrer L Histological and immunohistochemical study of clinically normal skin of Leishmania infantum-infected dogsJ Comp Pathol2004 1301712
Not in our library10.1016/s0021-9975(03)00063-x
41.
Pena MT Naranjo C Klauss G Fondevila D Leiva M Roura X Davidson MG Dubielzig RR Histopathological features of ocular leishmaniosis in the dogJ Comp Pathol2008 13813239
Not in our library10.1016/j.jcpa.2007.09.004
42.
Petanides TA Koutinas AF Mylonakis ME Day MJ Saridomichelakis MN Leontides LS Mischke R Diniz P Breitschwerdt EB Kritsepi M Factors associated with the occurrence of epistaxis in natural canine leishmaniasis (Leishmania infantum)J Vet Intern Med2008 224866872
Not in our library10.1111/j.1939-1676.2008.0129.x
43.
Mylonakis ME Papaioannou N Saridomichelakis MN Koutinas AF Billinis C Kontos VI Cytologic patterns of lymphadenopathy in dogs infected with Leishmania infantumVet Clin Pathol2005 343243247
Not in our library10.1111/j.1939-165x.2005.tb00048.x
44.
Mettler M Grimm F Capelli G Camp H Deplazes P Evaluation of enzyme-linked immunosorbent assays, an immunofluorescent-antibody test, and two rapid tests (immunochromatographic-dipstick and gel tests) for serological diagnosis of symptomatic and asymptomatic Leishmania infections in dogsJ Clin Microbiol2005 431155155519
Not in our library10.1128/jcm.43.11.5515-5519.2005
45.
Mohebali M Taran M Zarei Z Rapid detection of Leishmania infantum infection in dogs: comparative study using an immunochromatographic dipstick rk39 test and direct agglutinationVet Parasitol2004 1213-4239245
Not in our library10.1016/j.vetpar.2004.02.014
46.
Ferroglio E Centaro E Mignone W Trisciuoglio A Evaluation of an ELISA rapid device for the serological diagnosis of Leishmania infantum infection in dog as compared with immunofluorescence assay and Western blotVet Parasitol2007 1441-2162166
Not in our library10.1016/j.vetpar.2006.09.017
47.
Maia C Ramada J Cristovao JM Goncalves L Campino L Diagnosis of canine leishmaniasis: conventional and molecular techniques using different tissuesVet J2009 1791142144
Not in our library10.1016/j.tvjl.2007.08.009
48.
Solano-Gallego L Rodriguez-Cortes A Trotta M Zampieron C Razia L Furlanello T Caldin M Roura X Alberola J Detection of Leishmania infantum DNA by fret-based real-time PCR in urine from dogs with natural clinical leishmaniosisVet Parasitol2007 1473-4315319
Not in our library10.1016/j.vetpar.2007.04.013
49.
Maia C Campino L Methods for diagnosis of canine leishmaniasis and immune response to infectionVet Parasitol2008 1584274287
Not in our library10.1016/j.vetpar.2008.07.028
50.
Miro G Cardoso L Pennisi MG Oliva G Baneth G Canine leishmaniosis--new concepts and insights on an expanding zoonosis: part twoTrends Parasitol2008 248371377
Not in our library10.1016/j.pt.2008.05.003
51.
Pennisi MG Reale S Giudice SL Masucci M Caracappa S Vitale M Vitale F Real-time PCR in dogs treated for leishmaniasis with allopurinolVet Res Commun2005 29Suppl 2301303
Not in our library10.1007/s11259-005-0067-4
52.
Manna L Reale S Vitale F Picillo E Pavone LM Gravino AE Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinolVet J2008 1772279282
Not in our library10.1016/j.tvjl.2007.04.013
53.
Reis AB Teixeira-Carvalho A Vale AM Marques MJ Giunchetti RC Mayrink W Guerra LL Andrade RA Correa-Oliveira R Martins-Filho OA Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasiVet Immunol Immunopathol2006 1123-4102116
Not in our library10.1016/j.vetimm.2006.02.001
54.
Noli C Auxilia ST Treatment of canine Old World visceral leishmaniasis: a systematic reviewVet Dermatol2005 164213232
Not in our library10.1111/j.1365-3164.2005.00460.x
55.
Ikeda-Garcia FA Lopes RS Marques FJ de Lima VM Morinishi CK Bonello FL Zanette MF Perri SH Feitosa MM Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniateVet Parasitol2007 1433-4254259
Not in our library10.1016/j.vetpar.2006.08.019
56.
Ribeiro RR Moura EP Pimentel VM Sampaio WM Silva SM Schettini DA Alves CF Melo FA Tafuri WL Demicheli C Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniateAntimicrob Agents Chemother2008
Not in our library10.1128/aac.00223-08
57.
Infectivity to <it>Phlebotomus perniciosus </it>of dogs naturally parasitized with <it>Leishmania infantum </it>after different treatments · 2011
Not checked
58.
Pennisi MG De Majo M Masucci M Britti D Vitale F Del Maso R Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycinVet Rec2005 15611346349
Not in our library10.1136/vr.156.11.346
59.
Torres M Bardagi M Roura X Zanna G Ravera I Ferrer L Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinolVet J2011 1883346351
Not in our library10.1016/j.tvjl.2010.05.025
60.
Oliva G Scalone A Foglia Manzillo V Gramiccia M Pagano A Di Muccio T Gradoni L Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and nested-PCR techniques in a cohort of naive dogs exposed to three consecutive transmission seasonsJ Clin Microbiol2006 44413181322
Not in our library10.1128/jcm.44.4.1318-1322.2006
61.
Miro G Galvez R Mateo M Montoya A Descalzo MA Molina R Evaluation of the efficacy of a topically administered combination of imidacloprid and permethrin against Phlebotomus perniciosus in dogVet Parasitol2007 1433-4375379
Not in our library10.1016/j.vetpar.2006.09.014
62.
Mencke N Volf P Volfova V Stanneck D Repellent efficacy of a combination containing imidacloprid and permethrin against sand flies (Phlebotomus papatasi) in dogsParasitol Res2003 90Suppl 3S108111
Not in our library10.1007/s00436-003-0905-7
63.
Killick-Kendrick R Killick-Kendrick M Focheux C Dereure J Puech MP Cadiergues MC Protection of dogs from bites of phlebotomine sandflies by deltamethrin collars for control of canine leishmaniasisMed Vet Entomol1997 112105111
Not in our library10.1111/j.1365-2915.1997.tb00298.x
64.
Otranto D Paradies P Lia RP Latrofa MS Testini G Cantacessi C Mencke N Galli G Capelli G Stanneck D Efficacy of a combination of 10% imidacloprid/50% permethrin for the prevention of leishmaniasis in kennelled dogs in an endemic areaVet Parasitol2007 1443-4270278
Not in our library10.1016/j.vetpar.2006.09.012
65.
Maroli M Mizzon V Siragusa C D'Oorazi A Gradoni L Evidence for an impact on the incidence of canine leishmaniasis by the mass use of deltamethrin-impregnated dog collars in southern ItalyMed Vet Entomol2001 154358363
Not in our library10.1046/j.0269-283x.2001.00321.x
66.
Foglia Manzillo V Oliva G Pagano A Manna L Maroli M Gradoni L Deltamethrin-impregnated collars for the control of canine leishmaniasis: evaluation of the protective effect and influence on the clinical outcome of Leishmania infection in kennelled stray dogsVet Parasitol2006 1421-2142145
Not in our library10.1016/j.vetpar.2006.06.029
67.
Otranto D de Caprariis D Lia RP Tarallo V Lorusso V Testini G Dantas-Torres F Latrofa S Diniz PP Mencke N Prevention of endemic canine vector-borne diseases using imidacloprid 10% and permethrin 50% in young dogs: a longitudinal field studyVet Parasitol2010 1723-4323332
Not in our library10.1016/j.vetpar.2010.05.017
68.
Gavgani AS Hodjati MH Mohite H Davies CR Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trialLancet2002 3609330374379
Not in our library10.1016/s0140-6736(02)09609-5
69.
Alexander B Maroli M Control of phlebotomine sandfliesMed Vet Entomol2003 171118
Not in our library10.1046/j.1365-2915.2003.00420.x
70.
Maroli M Gradoni L Oliva G Castagnaro M Crotti A Lubas G Paltrinieri S Roura X Zini E Zatelli A Guidelines for prevention of leishmaniasis in dogsJ Am Vet Med Assoc2010 2361112001206
Not in our library10.2460/javma.236.11.1200
71.
Rossi E Bongiorno G Ciolli E Di Muccio T Scalone A Gramiccia M Gradoni L Maroli M Seasonal phenology, host-blood feeding preferences and natural Leishmania infection of Phlebotomus perniciosus (Diptera, Psychodidae) in a high-endemic focus of canine leishmaniasis in Rome province, ItalyActa Trop2008 1052158165
Not in our library10.1016/j.actatropica.2007.10.005
72.
Borja-Cabrera GP Correia Pontes NN da Silva VO Paraguai de Souza E Santos WR Gomes EM Luz KG Palatnik M Palatnik de Sousa CB Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN)Vaccine2002 2027-2832773284
Not in our library10.1016/s0264-410x(02)00294-3
73.
Palatnik-de-Sousa CB Barbosa Ade F Oliveira SM Nico D Bernardo RR Santos WR Rodrigues MM Soares I Borja-Cabrera GP FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccineExpert Rev Vaccines2008 76833851
Not in our library10.1586/14760584.7.6.833
74.
Lemesre JL Holzmuller P Goncalves RB Bourdoiseau G Hugnet C Cavaleyra M Papierok G Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trialVaccine2007 252142234234
Not in our library10.1016/j.vaccine.2007.02.083
75.
Saraiva EM de Figueiredo Barbosa A Santos FN Borja-Cabrera GP Nico D Souza LO de Oliveira Mendes-Aguiar C de Souza EP Fampa P Parra LE The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccineVaccine2006 241324232431
Not in our library10.1016/j.vaccine.2005.11.061
76.
Fernandes AP Costa MM Coelho EA Michalick MS de Freitas E Melo MN Luiz Tafuri W Resende Dde M Hermont V Abrantes Cde F Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 proteinVaccine2008 264658885895
Not in our library10.1016/j.vaccine.2008.05.095
77.
Diza E Kansouzidou A Gerou S Vezyri E Metallidis S Antoniadis A Leishmaniases in Northern Greece: seroprevalence of the infection and incidence of the disease during the period 2001-2006Eur J Clin Microbiol Infect Dis2008 27109971003
Not in our library10.1007/s10096-008-0538-y
78.
Marty P Izri A Ozon C Haas P Rosenthal E Del Giudice P Godenir J Coulibaly E Gari-Toussaint M Delaunay P A century of leishmaniasis in Alpes-Maritimes, FranceAnn Trop Med Parasitol2007 1017563574
Not in our library10.1179/136485907x229121
79.
IRIS staging of chronic renal diseasehttp://www.iris-kidney.com/guidelines/en/staging_ckd.shtml
Not in our library
80.
IRIS treatment recommendationhttp://www.iris-kidney.com/guidelines/en/treatment_recommendations.shtml
Not in our library
81.
Denerolle P Bourdoiseau G Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases)J Vet Intern Med1999 135413415
Not in our library10.1111/j.1939-1676.1999.tb01455.x
82.
Bianciardi P Brovida C Valente M Aresu L Cavicchioli L Vischer C Giroud L Castagnaro M Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneysToxicol Pathol2009 376770775
Not in our library10.1177/0192623309344088
83.
Miro G Oliva G Cruz I Canavate C Mortarino M Vischer C Bianciardi P Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosisVet Dermatol2009 205-6397404
Not in our library10.1111/j.1365-3164.2009.00824.x
84.
Mateo M Maynard L Vischer C Bianciardi P Miro G Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosisParasitol Res2009 1051155162
Not in our library10.1007/s00436-009-1375-3
85.
Manna L Vitale F Reale S Picillo E Neglia G Vescio F Gravino AE Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosisVet J2009 1823441445
Not in our library10.1016/j.tvjl.2008.08.009
86.
Koutinas AF Saridomichelakis MN Mylonakis ME Leontides L Polizopoulou Z Billinis C Argyriadis D Diakou N Papadopoulos O A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosisVet Parasitol2001 984247261
Not in our library10.1016/s0304-4017(01)00399-5
87.
Plevraki K Koutinas AF Kaldrymidou H Roumpies N Papazoglou LG Saridomichelakis MN Savvas I Leondides L Effects of allopurinol treatment on the progression of chronic nephritis in Canine leishmaniosis (Leishmania infantum)J Vet Intern Med2006 202228233
Not in our library10.1111/j.1939-1676.2006.tb02850.x
88.
Cavaliero T Arnold P Mathis A Glaus T Hofmann-Lehmann R Deplazes P Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantumJ Vet Intern Med1999 134330334
Not in our library10.1111/j.1939-1676.1999.tb02190.x
89.
Ling GV Ruby AL Harrold DR Johnson DL Xanthine-containing urinary calculi in dogs given allopurinolJ Am Vet Med Assoc1991 1981119351940
Not in our library

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.